This year’s general sessions feature distinguished speakers sharing innovative trends and trailblazing research in clinical practice. Tait Shanafelt, MD AACE 2020’s keynote speaker is Tait Shanafelt, MD, Stanford University’s first Chief Wellness Officer. A medical oncologist by training, Dr. Shanafelt is a leading researcher on physician burnout and its impact on quality of care, access, and physician availability. In a 2015 study that he co-authored, Dr. Shanafelt and his colleagues reported that burnout and satisfaction with work-life balance in U.S. physicians worsened from 2011 to 2014. In fact, more than half of all U.S. physicians, the researchers wrote, are now experiencing professional burnout. That’s not good for physicians, and it’s certainly not good for patients. In this opening keynote, Dr. Shanafelt will address the factors – including the rapid, often overwhelming introduction of health IT, including EHRs – that contribute to burnout and what must be done to recalibrate physician work-life balance and, concurrently, improve the quality of patient care. Meryl S. LeBoff, MD Meryl S. LeBoff, MD is a Professor of Medicine at Harvard Medical School (HMS) and the Brigham and Women’s Hospital (BWH), Distinguished Chair in Skeletal Health and Osteoporosis. She is Chief of the Calcium and Bone Section in the Division of Endocrinology, Diabetes and Hypertension at Brigham and Women’s Hospital (BWH) and directs the Skeletal Health and Osteoporosis Center and Bone Density Unit, which she founded. As an endocrinologist, Dr. LeBoff specializes in osteoporosis, fracture outcomes, metabolic bone diseases and disorders of calcium homeostasis. From evidence of a high prevalence of vitamin D deficiency in women admitted to BWH with hip fractures, she advanced the care of hip fracture patients with implementation of an inter-disciplinary fracture pathway with her colleagues in the Department of Orthopedic Surgery in what is now a Fracture Liaison service - Brigham Fracture Intervention Team pathway or “B-FIT©”. Dr. LeBoff’s research focuses on: bone health across the life cycle from young adulthood to extreme old age; vitamin D and bone health, fractures, musculoskeletal function and falls; risk factors for osteoporosis (including low vitamin D levels, hormonal modifiers on bone, and medical disorders or therapies that lead to low bone mass); and new approaches to imaging bone density and structure and body composition. Dr. LeBoff was the contributing author to the Surgeon General’s Report on Bone Health and Osteoporosis on “Vitamin D intake across the life course." She served on the central Calcium, Vitamin D, and Osteoporosis Committee for the large Women’s Health Initiative (WHI) since 1993 and WHI ancillary studies. Dr. LeBoff served as a Council member for the American Society for Bone and Mineral Research. She serves on the Board of Trustees for the United States Bone and Joint Initiative and the National Osteoporosis Foundation, in research grants sponsored by NIAMS. She is the PI on two ancillary studies to the large VITamin D and OmegA-3 Fatty Acid Trial (VITAL), testing effects of supplemental vitamin D and /or omega-3 fatty acids vs. placebo on bone density and structure, body composition, physical performance measures and incident fractures in men and women. Sadaf Farooqi, PhD, FRCP, FMedSci Sadaf Farooqi is a Wellcome Principal Research Fellow and Professor of Metabolism and Medicine at the University of Cambridge, UK. She is an internationally recognized clinician scientist who has made seminal contributions to understanding the genetic and physiological mechanisms that underlie severe obesity and its complications. The work of Sadaf Farooqi and her colleagues has fundamentally altered the understanding of human body weight regulation and obesity. With colleagues, she discovered and characterised the first genetic disorders that cause severe childhood obesity and established that the principal driver of obesity in these conditions was a failure of the central control of appetite. Her work is often cited as an exemplar of how the translation of research into the basic mechanisms of disease can lead to patient benefit. Kenneth Cusi, MD, FACE Kenneth Cusi, MD, serves as Chief of the Division of Endocrinology, Diabetes & Metabolism in the Department of Medicine at the University of Florida. He received his medical degree in Argentina from the University of Buenos Aires School of Medicine and is board certified in both Internal Medicine and Endocrinology, Diabetes & Metabolism. He completed his residency at the Center of Medical Education & Clinical Research (CEMIC) in Buenos Aires, Argentina, and a clinical fellowship at Baylor College of Medicine in Houston. Prior to joining the University of Florida, Dr. Cusi was a faculty member of over 15 years in the Diabetes Division at the University of Texas Health Science Center at San Antonio (UTHSCSA) and the Veterans Health Administration System in Texas - one of the leading diabetes programs in the country. He is a fellow of the American College of Physicians (ACP) and the American Association of Clinical Endocrinologists (AACE). He has actively participated in many clinical diabetes programs and in the training of many young researchers and clinicians. He is the principal investigator of various ongoing clinical translational research projects in obesity, Type 2 diabetes mellitus (T2DM) and nonalcoholic fatty liver disease (NAFLD). Desmond Schatz, MD Desmond Schatz, MD, is Professor and Interim Chairman of Pediatrics, Medical Director of the Diabetes Institute and Director of the Clinical Research Center within the CTSI at the University of Florida, Gainesville. He served as President of Science and Medicine of the American Diabetes Association in 2016. Dr. Schatz has been involved in Type 1 diabetes research since the mid 1980s and has published over 360 manuscripts, the majority related to the prediction, natural history, genetics, immunopathogenesis and prevention of the disease, as well as the management of children and adolescents with Type 1 diabetes. He is the Principal Investigator (Pl) on several NIH awards. He is the Pl of the University of Florida Clinical Center participating in the NIH-funded TrialNet (a founding member of the DPT-1 in 1994). He is co-Pl on a program project grant seeking to understand the immunopathogenesis of Type 1 diabetes, and also serve as Pl for the NIH-funded international newborn genetic screening (TEDDY) program in North Central Florida. He is the Pl on the NIH-funded Human Islet Research Network (HIRN) Grant evaluating novel markers and mechanisms of beta cell destruction. He is the Pl of the University of Florida site participating in the Type 1 Diabetes Exchange. Dr. Schatz has served in numerous capacities (committees, study sections) for the American Diabetes Association, JDRF and NIH. He serves on the external advisory board for the NIH- and CDC-funded SEARCH and TODAY studies in youth with Type 2 diabetes and on the JDRF-funded Australian INIT II studies. He was awarded the Mary Tyler Moore and S Robert Levine JDRF Excellence in Clinical Research Award, the 2009 Cure Award from the American Diabetes Association, the 2010 Public Policy Leadership Award, the prestigious Banting Medal for service from the American Diabetes Association and the ISPAD Prize for achievement (the highest honor of the International Society for Pediatric and Adolescent Diabetes.) Shalender Bhasin, MB BS Shalender Bhasin, MD, is a Professor of Medicine at Harvard Medical School, and Director of the Research Program in Men's Health, Aging and Metabolism, and Director of the Boston Claude D. Pepper Aging Research Center at the Brigham and Women's hospital in Boston, MA. Dr. Bhasin is an outstanding translational investigator, whose pioneering investigations have been notable for their bold study design, innovation, and their enduring impact in bringing resolution to some of the most controversial issues in reproductive endocrinology and in spawning a whole new biotechnology industry around the clinical applications of androgens and selective androgen receptor modulators (SARMs). Dr. Bhasin’s discoveries include characterization of testosterone’s biologic effects, its dose-response relationships in men and women, and its potential benefits and adverse effects. His research provided the first clear demonstration that testosterone increases muscle mass and strength, elucidated the mechanisms by which testosterone increases muscle mass and stimulates erythropoiesis, and clarified the role of steroid 5α-reductase type 2 in men. He chaired the Endocrine Society's expert panel that developed the guidelines for testosterone replacement therapy in hypogonadal men. Dr. Bhasin has led some of the most important randomized trials of testosterone in hypogonadal men, in older men with age related decline in testosterone, and in men and women with sarcopenia and functional limitations. These RCTs have clarified the benefits and risks of testosterone and formed the basis of the testosterone guideline, which he has led since 2005 through its three updates. He has led the efforts to generate harmonized, population-based reference ranges for testosterone in men, characterized testosterone’s binding to SHBG and described a new model for estimation of free testosterone. He has served as an Associate Editor of the JCEM and the Journal of Andrology, the Chair of the Clinical Guidelines and of the Expert Panel that developed guidelines for Testosterone Therapy, and Chair of ABIM Endocrinology and Metabolism Subspecialty Board. Dr. Bhasin’s numerous clinically-relevant discoveries have spawned new biotechnology ventures, patents, and over 300 high impact publications in top-tier journals such as the NEJM, JAMA, and PNAS, and have shaped the theory and practice of reproductive endocrinology.